CA1180009A

CA1180009A - Platinum complexes

Info

Publication number: CA1180009A
Application number: CA000394370A
Authority: CA
Inventors: Tetsushi Totani
Original assignee: Tetsushi Totani; Shionogi & Co., Ltd.
Current assignee: Shionogi and Co Ltd
Priority date: 1981-01-23
Filing date: 1982-01-18
Publication date: 1984-12-27
Also published as: AU557336B2; US4575550A; JPS57123198A; GB2091731B; JPS637194B2; GB2091731A; AU7976582A; EP0057023B1; EP0057023A1; DE3260164D1

Abstract

Abstract of the Disclosure Platinum complexes of the following formula useful as antitumor agents with less nephro-toxicity and higher water solubility than cisplatin:

Description

Ti-tle NO~EL PLATINUM CO~PLEXES
Back~round of the Inven-tion It has been known that various platinum compounds have antitumor activities, and for example, eisplatin (Jap.
OPI 49-7224), malonato(l,2-diaminocyelohexane)platinum(II) [Jap. OPI 53-31648], and sulfa-to(1,2-cliaminoeyelo~exane) platinum(II) [Jap. OPI 54-44620] have been reported as such eompounds.
The present inventors have investigated intensively to find the platinum eompounds which have more potent anti-tumor aetivity and less toxicity than the prior art compounds, and have aeeomplished the present invention.

,~

Brief Summary of the Iuverll;iorl The present invention relates to novel platinum complexes.
The platinulr1 compouncls in the present invention are represented by the follo~iing general formula (I).

3 Pt(II) (I) [wherein e.actl of X an-l Y is a mono-valent group represented by OCO ( Cr~l 2m m~ 1, ) O
_OCO-(Cnll2n_2JI-l) or X and Y taken together form a di-valent group reprcsented by -OCO-(C H O )-O-, m 2m m-l ~C~(cn~2n-2n-l)~~' or (wllerein m is an integer of 1 to 6, ancl n is an integer of 4 o~ 5 ) ]
The compounds of the formula (I) are obtained by the reaction of cis-diamminedinit~atoplatinum(II) of the formula: Pt(N~3)2(No3j2 witll the alkali Ine tal salts of ; hydroxycarboxyLic acicls, and may be ; adm:Lrll~tered parerlter,llly as antitllmor ~gent.C;~

~ - 2 ~

Detailed Descril:)tion In tlle formtlla (I), X and Y respectively or taken together represent a mono- or di-valent resiclue of hydro.Yy-carboYylic acicls. The hydroxycarboxylic acids are, e. g., glycolic acid, glyceri.c acid, gluconic acid, gulonic acid, glucoheptonic acid, galacturonic acid, glucuronic acid, etc., and besicles naturally occurring or synthe tically availablc! hydlo.Yycarbo.Yylic acids applicable to the above f'ornlula~ are lncluclecl in the present invention.
The typical llgarlcls rcprcserltecl by X and ~ are shown as follows.

-OCocH20l~ -OCOCH(OH)CH20H, -oco(cHoH)4c~2oH~ -OC()(CHOH)5CH20H, -OCO -OCO
HO ~ ~ o OH -OCO\

~ OH HO ~ j CH2 - OH OH

-OCO -OCO
/ CH-CH20H / CH(cHoH)3cHzoH
--O ' .' - -OCO -OCO
~CII~C~-~(J~ CII2O~ ~<L o~
L~oll o~l -oco ¦ OH

~ \J
_o \~
OH
Hydroxycarboxylic acids employed in the reaction for preparing the compounds (I) are represented by the general formula:
HOCO~(C ~l2 )-OH or HOCO (Cn 2n-2 n-l (wherein m and n have the same meanings as the above) which may be changed into the alkali metal salts pre-viously, if required. Hydroxycarboxylic acids are reacted with the objective alkali metal hydroxides to form the corresponding alkali metal salts. As the alkali metal salts, .
lithium salts, sodium salts, potassium sal-ts, etc. may be employed, and particularly the sodium salts are preferred.
For the cis-diamminedinitratoplatinum (II) an equivalent or excess amount, more preEerably 1-2 equivalents of hydroxy-carboxylic acids are employed in the reaction. More definite-ly, .it i~ aclequatq to u~e 2 equ.ivalen-ks o~ the acids in the roaction in ~rder to ob~ain ~hq complexe~ in whlch X
and Y arq ~ach a mono-va.lellt .I.icJand, and l equivcl~

lent in order to obtairl t;lle cor1lpl(?Yes .in ~hich ~ arl(l Y taken to-getller-form a ~ va:Lent Ligar]cl. The reaction may be carried ou-t under heating, preferablv at ~0 - 70C.
The compounds in the present inventiorl include not only those defined as ligands of` the formula (I), but also all of the platlnum cornple.Yes obtained by the reaction of the cis-diammine(lirlltratopLati.llum(II) ~ith the above-mentioned hyclro~ycarbo~ylic acicls ~ithin ~lle s.cope of the preserlt :inverltiorl.
The compolln-ls in tlle preserlt invetltiorl have apploxi-mately -the sarne activitv as or more potent an-titumor activity with less nephro-to~icity than cisplatin. Furthermore, they can easily be adminis-tered because of their high water solu-bility.
The compounds of -tile present invention can be administered to hwnan or animals parenterally. For e~ample, t~le compourlds (I), disso.Lved o:r suspended in proper solvents for injection (e. g., distillecl~ater for injection, physio-logical saline, 5 CO glucose aqueous solution, aqu.eous ethanol, a.queous glycerin, and aqueous propvlqne glycol), can be ad-ministered intraveneously, intramuscularLy, or subcutaneously, o:r by rnqarls o~ :i.nst:iLlat:iorl. Th~ compoLItlds (:r) can be pLaced :Ln t:Lghtly closed ampo~ s as a soLul;:Lorl or.~ a ~usp(~ i.i.orl, ~ncl morc pr~erably prescrvecl :itl a~ )ollles or vl~ls 11-l forrlls o~ crystals, ~o~d~rs, ~ crystal.s, :I.yoplli.l..izat;e, et;c , ' ~

~8~

so as to be dissolved immediately before use. Stabilizer may also be adcled.
In application for treatment of tumors, the compounds (I) may be administered paren-terally to an adult at a daily dose of 100 to 500 mg 1 to 3 times a day.
The following examples and experimen-ts will demons-trate the present inven-tion more in detail, The structural formulas shown in the examples are not definite, but o~ tentative.
Example 1 Diglucuronato-cis-diammineplatinum(II) ~ OH
NaOCO ~ OH

OH OH
cis-Pt(NH3)2(N03)2 O OH
OCO ~ ~ OH

H N / ~ \ o__~OH
OCO~ ~OE~

OH

The starting compound 1 [described in Indian J.
Chem. 8, 193 (1970)] (700 mg, 1.98 m mole) is dissolved in water ~70 ml) warmed a~ 60C, and sodium D-glucuronato mono-hydrate (936 mg, 4 m mole) is added thereto, After stirring for a short time, water is distilled o~f under reduced pressure with a rotary evaporator. The residue is washed with absolute methanol (90 ml) 5 times, and then dried under reduced pressure again. This is dissolved in a small amount of water, and methanol i9 gradually added thereto to release viscous colored substances. The supernatant is collected by decantation and evapora-ted to dryness under reduceci pres~ure. ~he residue is dissolved in water (5 ml) and khcn methanol ~80 ml) i9 added thereko to preci~itate the ~ltle oompound 2 a~ ~ colorle~s 301id. ~hi~ i~ wa3hed with methanol a~ ether ~ucce~ively, and dried under reduced pres~ure.

. . .

3~
Yield 650 ~n~ (54 ~p) mp ~ 150C (decomp.) Elemental Analysis (for Cl2H24ol4N2pt) Calcd. (%): C, 23.42; H, 3.93; N, 4.55; P-t, 31.70 Found. (~): C, 22.27; H, 4.23; N, 4.74; Pt, 31.49 IR: ~ aJl ~ 3400 (broad, -OH), rv3270(broad, -NH), 1633 (C=O), 1400, 1285, 1151, 1047, 1020, 952, 9.00, 798 cm 1.
Example 2 Glucuronato-cis-diammineplatinum(II) OH

NaOCO ~ ~ OH
> < ' cis-Pt(NH3)2(N03)2 OH OH
, >

O O

H3N > O ~ ~ OH

OH 0~

The starting compound 1 (127 mg, o.36 m mole) is dissolved in water (12 ml) warmed at 60C, and sodium D-glucuronate monohydrate ~85 m~, o,36 m mole) i5 added thereto and cli~olvecl therein, ~he mix-kur~ ls adjusted at pH 7 with a ~odium hyclroxicle ~q~eous solution, ancl wat~r is distilled o~ undor reduced pressure at 55C wit~ a rotary evaporator.

* trad~ mark The resulting colored residue is washed with absolute methanol (120 ml~ and evaporated to dryness under reduced pressure again. The residue is dissolved i~ a small amo~t of water and gradual addition of methanol yields viscous colored substances. The supernatant is collected by decantation and condensed to dryness. The residue i5 d:issolved in water (2 ml), and methanol (80 ml) is added thereto to precipitate the title compound ~ as a colorless sol:id. This is washed with methanol and ether successively, and then dried under reduced pressure.
Yield 65 mg (45 %) mp 170 - 180C (decomp.) Elemental An~lysis (for C6Xl5N207Pt) Calcd. (%): C, 17.07; H, 3.58; N, 6.63 Eound. (~): C, 16.39; H, 3.58; N, 6.15 IR: vNUJL ^_3380 (broad, -OH), ~3280 (broad, -NH), 1628 (C=O), 1406, 1148, 1105, 1046, 1015, 951, 824 cm~l, Example 3 .. . ..
Digluconato-cis-diammineplatin~n(II) NaOCO(CHOH)l~CH20H
cls-Pt(l~I3)2(N03)2 ----H3N~, " OCO ( C~IOH) ~cH2o}I
H3N f ~' OCO ( CHOH) l~CH20H

8~

The starting compo~md 1 (240 mg, o.68 m m,ole) is dissolved in water (24 ml) warmed at 60C, sodiu~ gluconate (301 mg, 1.38 m mole) is added thereto, and the mixture is stirred for a short time. The mixture is condensed to dryness at about 55C with a rotary evaporator. The residue is washed with a'bsolute methanol (80 ml) and evaporated to dryness under reduced pressure again. The residue is treated ln the same manner as ilL Example 1 to yield the title compound 4 (147 mg, yield 45 %) as a colorless solid.
mp 48 - 53C (hygroscopic and deliquescent) Elemental Analysis (for C12H28N2014Pt) Calcd. (%): C, 23.27; H, 4.56; N, 4.52 Found. ~%): C, 22.00; H, 4.53; N, 4.91 IR: ~max 3415 (broad, -OX), 3290 (broad, -NH), 1632 (C=O), 1132,- 1086, 024, 883 cm 1.
Example 4 'Gluconato-cis-diammineplatinum(II) NaOCO(CHOH)4CH20H
cis-Pt(NH3)2(N03)2 ~ >
-N / ~ O

~I3~ ' (c~IOH33cH2oH

' ' The starting compound 1 (240 m~, o.68 rn mole) i~

dissolved in water (24 ml) warmed at 60Ct and sodium gluconate (153 m~, 0.70 m mole) is added thereto and dissolved therein.
The mixture is adjusted at pH 7 with a sodium hydroxide aqueous solution and then water is distilled off under red~lced pressu~e at 55 - 60C with a rota~y evaporator. Then the residue is treated in the same manner as in Example 2 to yield th~ title compound ~ (74 mg, yield 25 ~) as a colorless hydrogroccopic solid.
m~ ^_120C (decomp.) Elemental Analysis (for C6H16N207Pt) Calcd. (~): C, 17.03; H, 3.81; N, 6.62 Found. ~%): C, 15.80; H, 3.86; N, 6.68 IR: ~NaJl ~_3400 (broad, -OH), ~3280 ~broad, -NX), 1632 (C=O), 1131, 1086, 1041, 866, 82~ cm 1.
Example 5 Digl~coheptonato-cis-diammineplatinum(II) NaOCO(CHOH)5CH20H
cis-Pt(NH3)2(N03)2 _ H3N\ / OCO~CHOH)5CH20H

H3~ / ~ 0CO(CHOH)5CH20 T~e ~tart.in~ compound 1 (LOO mg, 0.28 m molo) i~
dls~Qlved ln water (10 ml) warmed a~ 60~C, ~odlum glucohoptonatc .
-- 11 ~

dihydrate (162 mg, 0.57 m mole) is added thereto and dissolved therein. After stirring for a short time, the mixture is condensed to dryness at 55C with a rotary evaporator. The - residue is ~ashed with absolute methanol (80 ml) and evaporated to dryness under reduced pressure again. The residue is treated in the same manner as in Example 1 to yicld the title compound 6 (75 mg, yield 39 ~) as a colorless hygroscopic and deliquescent solid.

mp 78 - 85 C
Elemental Analysis (for C14H32N2016Pt) Calcd. (~: C, 24.75; H, 4.75; N, 4.12 ~ound. (~): C, 23.49; H, 4.79; N, 4.60 IR: ~ uJol 3230 ~broad, -OH, -NH), 1620 ~C=O), 1075, 1024, 884 cm 1.
Example 6 Glucohep,tonato-cis-diammineplatinum(II) cis-Pt(NH3)z(N03)2 NaOCO(CHOH)5CH20H

3--P t /
3 ( C}IOH)I~CH20H
~ .'. .
Tl~ artin~ compound 1 (1~0 m~, Q.3~ m mole) i9 dl~ol~ed ln water (12 ml) warmed at 60C; and qodium gluco-heptonat~ dihydrate (97 m~, 0.34 m mole) is added thereto and ~ 12 -dissolv~d therein. The mixture is adjusted at pH 8 ~ith a sodium~hydroxide aqueous solution, and water is distilled off under reduced pressure at 55C with a rotary evaporator.
~ The residue is ~ashed with absolute methanol (60 ml), and evaporated to dryness again. The residue is treated in the same manner as in Example 2 to yield the title compound 7 (47 m~, 30 ~) as a colorless solid.
mp 155 - 160C (decomp.) ~lernental Analysis ~for C7H13N208Pt) Calcd. (%): C, 18.55; H, 4.00; N, 6.18 Found. (~): C, 17.80; H, 4.24; N, 6.o7 IR: vmaJ 1 3425 (broad, -OH), 3285 (broad, -NH), 1612 ~C=O), 1085, 1029, 844 cm 1.

.

- 13 ~

ExE e ent 1 A;ltitumor activitY a,~ainst Sarcoma-180 ( Te s t Me thod ) 1~

~:~L8~

Sarcoma l~O tumor cells (5 x 106 cells) are in-oculated to DS mice (6 to 8 mice are employed in each test group) subcutaneously, and a predetermined an70unt of the test compounds is administered intraperitoneally for 5 days continuously from the next day of the inoculation.
(Test Compound) (A) Glucuronato-cis-diammineplatinum(I~) 0~
OCO ~ ~ OH

3 \ Pt / HO OH

H3N / \ OH

OCO ~ OH

HO OH

(produced in Example l) (B) Cisplatin (Evaluation of the Effect) On the 10th day after the inoculation of tumors, the mice are anatomized, the weight of tumors are mea~ured and comp~red wi-th that of the untrea-ted control group, and ~170 ~Pfcc~ l~ evall1ated from the effectivc do~e ~ED50) wh~ch i~iblt~ t~e ~rowt~ Or turllors by 50 ~, the 50 ~ lethal dose (LD5~), and the curatlve index (CI) .

~ 15 ~

* CI =

The larger CI is, the mo~e effective the compound is.
(Result) i) In the use of 5 % glucose solution as a solvent for injection . Compound (B) ___ ED5033~4 mg/kg 5.8 mg/kg LD5093~4 mg/kg 14.2 mg/kg CI 2.8 ~.4 ii) In the use of 0.9 ~ NaCl, 0.4 % Polysorbate 80, 0.5 % CMC, and 0.5 % benzyl alcohol suspension as a solvent for injection . _ _ Compound (A) (B) __ _ 34 ~ 7.3 mg/kg LD50 113.5 mg/kg 28.3 mg/kg . .
CI 3.3 3.9 (Te~ Method) ~ 16 ~

, ~18~

Leukemia Ll210 ascites cells (105 cells) in mice are;intraperitoneaLly lnoculated to BDFl mice (4 to 10 mice are employed in each test group), and on the next day a predetermined amount of the test compounds is ad-ministered intraperitoneally. The solvent for injection consists of 0.9 ~p NaCl, 0.4 ~ Polysorbate 80, o . 5 ~ CMC,' and 0.5 % benzyl alcohol suspension.
(Test Compound) The same as in Experiment 1 (Evalu~tion of the Effect) ~ rom the average survival days (a) in the test group and those (b) of the untreated control group, the increase of lifespan (ILS) is calculated according to the following expression.

ILS (~) = (a) - (b) (b (Result) ~ Compound _ .' I ~ () .

4 (q~) 1l (0_ 5 x 1 _ 12 ` 2 10 x 1 ____ ?81 ~ ~ .~ _ . 20 ~ 1 >55 _ _26 Experlment 3 Nephro-toxicity (Test Method) - Seven weeks-old male Sprague Dawley rats are separately acco~modated in metabolic cages of stainless steel, and solid feed (Clea Japan, INC., CA-l for breeding) and water are given so that they can take them freely.
They are adapted for 3 days and then the test compounds are once administered to rats intraperitoneally a-t 10:00 a. m. The test compounds are dissolved in 5 ~ glucose injection solution to give a 10 mg/7.5 ml solution im-mediately before use, and administered at a rate of 0.75 ml/ 100 g body weight. The urine excreted during a period of 10 a. m. on the day of administration to 10 a. m. on the next day is de~ined as urine of the first day; on the urine of the 0 - 4th days the volume of urine excreted, creatinine, osmotic pressure, urinary enzyme N-acetyl-~-D-glucosaminidase (NAG), and lysozyme (LEZ) are measured, and further urinary protein and urinary sugar are examined with Lab~tl ~. In the morning on the 5th day the rats are anatomized under anesthesia with Ouropan-Soda~ (Shionogi Co., Ltd.; ~exobarbital sodium), and the blood and pa~o-lo~io specimen~ oP the kldney and the liver are collected in order to determine t~e level of pla~ma urea nitrogen and creatlnlne, and osmo-tic pre~ure.

18 ~

(Test Compound) The same a~ in Experiment l (Result) . _ _ Test Compound Item of Observation ~ (A)~.; (B) ~ _ Dose (Once, i. p.) lO mg/kg 5 mg/kg Solvent for Injectlon .
Body Weigh-t (g) + ~
Volume of Urine (ml/24hrs.) + ~ 5 Excrement of Creatinine *
(m~2~hrs./lOOgBW) Osmotic Pressure of Urine (mOsm/kg) Excrement of Solute ~
~mOsm/24hrs./lOOgBW) _ + . +
NAG ~ .
LEZ +.
Plasma Urea Nitrogen +
Plasma Crea-tinine +
Creatinine Clearance +
Plasma Osmotic Pressure i -. __ .
Kidney Weight i Liver Weight +
__ . , ,.. _ _ _ . . _~ _ . __ Urinary Prctein + ~
Urln~xy Gluco~e _ _ _ (~o-tq~ ) * : The ~olvqnt ~or ;Ln~ec~i.on i~ 5 ~ glucose in and physiologlcal ~ali~e in : increase : slight increase ~ : decrease + : no change From the abo~e results, the effect on the ~unction o~ the kidney and the action on the whole body are great in cisplatin, but the presently claimed compound has little influence on them.

' ' ' .

- 20 ~
' SUPPLEMENTA~Y DISCLOSURE

E~ample 7 Glycolato-cis-diammineplatirlum(II) NaOOCCH20H H3L~ /O
CiS-Pt(~I3)2(NO3)2 > H3~/ \J

T~e starting compound 1 (706 mg, 2.0 m mole) is dlssolved in water (30 rrll) warmed at 60C, arld sodium ~lycolic acid (196 rng, 2.0 m mole) i~ added thereto arld dissolved -thereirl. The mi.Y-ture is adjusted at pH 7 ~ith a sodiwn hydroxide aqueous solution and stirred for 3 hours.
Water is distilled off L~der reduced pressure at about 50~C, and -the rernaining solid is washed with a small amount of chilled water and dried Lmder r~duced press~lr~
to yield the title compoLmd 8 (92 rng, 15 ~p).
mp 120C -~(decomp.) Elemental Analysis (~or C2H~N203Pt) Calcd. (~o): C, 7,92; HJ 2.66; N! 9.24; Pt, 64.34 Found. ($) c, 7.77; H, 2.71; ~r, 9.34; Pt, 64.L4 IR: ~ J 3290sh, j210s, 1620s, L580s, 144~rn, 1330n~, 131jm, 1060s, 925m, 900w, 860m, 755rn cm~l.
IR: (D20 ~olutiQn, ppm ~ron~ T~lS as th~ r3~Yternal standard, ~ .5~ (~ly~oLato C~l2' J195Pt-H 33 I?~ mDle 8 Glycr-3rato-ols-di,~mrll.irleplatinLIm( lI) NaOOCC~(OH)C~20H H3N ~ / 0--~
cis-P-t(N~I3)~(N03)2 ~ Pt\
3 o ~ CH20H
l 9 In the same manner as in E~ample 2 the title compound 9;is given in 45 ~o yield.
mp 130C - (decomp.) EleLnen~al Analysis (fo~ C3Hlo~T2ol~pt) Calcd. (~): C, :L0.8L; H, 3.03; N, 8.41; Pt, 58.5 Found. (~o): C, 10.99; H, 3.42; ~, 8.47; P-t, 58.15 IR: - vNUJl 3400sh, 3130s, 1600s, 1560s, 1360m, 1330rn, 1280w, 1225w, 1105w, 1070m, lOOOm, 910w, 850~, 720m cm~l-E~N~: (D20 solution , ppm from T~S as the e~ternal sta~dard,~) 4.05 - 4.45 (m, glyceryl CH2), 4.40 - 4.~0 ~m, glyceryl CH) E mple 9 ! Diglycolato-cis-diammineplatim.~(II)

2~TaOO~CH20H H3~T~ ~ ococH2oH
cis-Pt(N~I3)2(N03)2 ~ H3`T/ ~ ococH2oH

ln the 5ame marLner a~, in E~Yarnple l the title c ~mpQL~nd lO is given ln 79 ~q y-Le Ld .
mp 13(~qC ~ (ClqCOrllp~ ) Elenlentsll Analysi~

~ j 2~ -Calcd, (~p): C, 12,67; ~I, 3.19; ~, 7.39; Pt, 51,44 Follnd. (~o): C, 12.38; H, 3,29; N, 7.43; P-t, 50.97 IR: yNljOl 3250sh, 3200s, 1620s, 1580s, l440m, L330m, max 1320m, 1060s, 930m, 900w, 860~, 760w, 720w cm : (D20 sol-ltion. pp~ from T~IS as the e.Yternal standard, ~ ,51 (glycc~:lato CH2), 3-5 - 5~5 (~I3) Exa~_e 10 Diglycerato-cis-diaounineplatin~n(II) ; . 2NaOOCCH(OH)CH20H H ~ / OcOcH(OH)cH OH
cis-Pt(lYH3)2(N3)2 ~ 3 Pt 2 H3~/ ~ OCOCH(OH)CH20H

In -the same ma~ner as in Example 1 the ti~le compound li is given in 86 ~p yield, mp 70 - 80C
Elemental Analysis (for C6H16N208Pt) Calcd, (~o): C, 16 40; H, 3,67; N, 6,38; Pt, 44,40 FoLlnd. (~o): C, 15-73; H. 3.84; N, 6,97; Pt, 45.86 IR: v n~Y 3350sh, 3240s, 1620s, lllOm. 1060m, lOOOm, 870w, 820w. 770w, 720w cm 1, (D20 .~olLIt:ion~ ppm fro((l TI~IS a5 the qYt~tn,ll ~tanch~rcl, ~) 4.13 ~ l (m. ~lycqrato CH2), 4.57 _ 4~75 (m~
~lycqrato CH), 3~0 ~ 5,l~o ~N~13) ~8~

Experiment 4 Antitumor activit-y a~alnst Sarcoma-18_ (Test Method) The test was carried out in the same ma~ner as in Experiment 1, wherein the test co~lpounds were administered i~.tra~enously for 5 days.
(Test Compollnd) (A) Glucuronato-cis-diarrlm:ineplatinum(II) (B) Cisplatin (C) Glycolato-cis-diammineplatinurn(II) H3N pt/ O

(produced in Eample 7) (D) DigLycolato-sis-diammineplatinum(II) H N / ococH2oH

3 ocOCH20H

(produced in Example 9) (E) Glycerato-cis-dian-mlneplatinum(II) 3 Pt H3N / ~ CH~OH

(yroducq~l in E~ampLf~ 8) ~valuation o~ th~7 ~e~t) ~`~e ~valLIc~Ltion ~as mad~ in the sam~ marLn~r as in E~pe ~imq n t 1 .

~ 2 ( Re s ul t ) Compound ¦ ~ ¦ B ¦ C ~ D ¦ E
l _ ED50 (rng/kg) 63-4 ¦4.5 18 7 24.1 L~4 _ _ _ LD50 ( mg/ g) 18614 . 2 86 . 6 80 . 0 186 . 6 l l _ C I ¦2 - 93 - 2 ¦ 4 - 63 34 . 2 ~* Administered as 5 ~ glllcose solutiorl.

25 ~

Claims

The embodiments of the invention in which an exclusive pro-perty or privilege is claimed are clefined as follows:

1. A process for preparing a platinum complex of the formula:

wherein each of X and Y is a mono-valent group of -OCO-(CmH2mOm-1)-OH or -OCO-(CnH2n-2On-1)-OH

or X and Y taken together form a divalent group of -OCO-(CmH2mOm-1)-O- or -OCO-(CnH2n-2On-1)-O-wherein m is an integer of 1 to 6, and n is an integer of 4 or 5, comprising reacting cis-diamminedinitratoplatinum (II) with a hydroxycarboxylic acid of the formula:
HOCO-(CmH2mOm-1)-OH or HOCO-(CnH2n-2On-1)-OH

wherein m and n each has the same significances as mentioned above.

2. The process of claim 1 wherein m is an integer of 5 or 6 and n is an integer of 5.

3. The process of claim 1 for the preparation of diglucuronato-cis-diammineplatinum (II), wherein the hydroxy-carboxylic acid is HOCO-(C5H8O4)-OH.

4. The process of claim 1 for the preparation of glucuronato-cis-diammineplatinum (II), wherein the hydroxy-carboxylic acid is HOCO-(C5H8O4)-OH.

5. The process of claim 1 for the preparation of digluconato-cis-diammineplatinum (II), wherein the hydroxy-carboxylic acid is HOCO-(C5H10O4)-OH.

6. The process of claim 1 for the preparation of gluconato-cis-diammineplatinum (II), wherein the hydroxy-carboxylic acid is HOCO-(C5H10O4)-OH.

7. The process of claim 1 for the preparation of diglucoheptonato-cis-diammineplatinum (II), wherein the hydroxycarboxylic acid is HOCO-(C6H12O5)-OH.

8. The process of claim 1 for the preparation of glucoheptonato-cis-diammineplatinum (II), wherein the hydroxycarboxylic acid is HOCO-(C6H12O5)-OH.

9. Platinum complexes of the formula:

wherein each of X and Y is a mono-valent group of -OCO-(CmH2mOm-1)-OH or -OCO-(CH2n-2On-1)-OH

or X and Y taken together form a di-valent group of -OCO-(CmH2mOm-1)-O-, or -OCO-(CnH2n-2On-1)-O-(wherein m is an integer of 1 to 6, and n is an integer of 4 or 5) when prepared by the process of claim 1.

10. Platinum complexes as claimed in claim 9, wherein m is an integer of 5 or 6 and n is an integer of 5 when prepared by the process of claim 2.

11. Diglucuronato-cis-diammineplatinum (II) when pre-pared by the process of claim 3.

12. Glucuronato-cis-diammineplatinum (II) when pre-pared by the process of claim 4.

13. Digluconato-cis-diammmineplatinum (II) when pre-pared by the process of claim 5.

14. Gluconato-cis-diammineplatinum (II) when prepared by the process of claim 6.

15. Diglucoheptonato-cis-diammineplatinum (II) when prepared by the process of claim 7.

16. Glucoheptonato-cis-diammineplatinum (II) when pre-pared by the process of claim 8.

CLAIMS SUPPORTED BY SUPPLEMENTARY DISCLOSURE

17. The process of claim 1 for the preparation of glycolato-cis-diammineplatinum (II), wherein the hydroxy-carboxylic acid is HOOCCH2OH.

18. The process of claim 1 for the preparation of glycerato-cis-diammineplatinum (II), wherein the hydroxy-carboxylic acid is HOOCCH(OH)CH2OH.

19. The process of claim 1 for the preparation of diglycolato-cis-diammineplatinum (II), wherein the hydroxy-carboxylic acid is HOOCCH2OH.

20. The process of claim 1 for the preparation of diglycerato-cis-diammineplatinum (II), wherein the hydroxy-carboxylic acid is HOOCCH(OH)CH2OH.

21. Glycolato-cis-diammineplatinum (II) when prepared by the process of claim 17.

22. Glycerato-cis-diammineplatinum (II) when prepared by the process of claim 18.

23. Diglycolato-cis-diammineplatinum (II) when prepared by the process of claim 19.

24. Diylycerato-cis-diammineplatinum (II) when prepared by the process of claim 20.